Guggenheim Initiates Coverage on enGene (NASDAQ:ENGN)

Guggenheim started coverage on shares of enGene (NASDAQ:ENGN) in a research report released on Monday, MarketBeat reports. The firm issued a buy rating and a $34.00 price target on the stock.

ENGN has been the topic of several other reports. Leerink Partnrs reiterated an outperform rating on shares of enGene in a research report on Tuesday, February 20th. Morgan Stanley assumed coverage on shares of enGene in a research note on Friday, March 8th. They issued an overweight rating and a $40.00 price objective for the company. SVB Leerink assumed coverage on shares of enGene in a research note on Tuesday, February 20th. They issued an outperform rating and a $31.00 price objective for the company. Finally, UBS Group began coverage on shares of enGene in a research note on Thursday, March 28th. They issued a buy rating and a $37.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of Buy and an average price target of $35.50.

enGene Stock Performance

Shares of enGene stock opened at $15.79 on Monday. The firm’s 50 day moving average is $15.39. enGene has a twelve month low of $6.69 and a twelve month high of $43.00.

Hedge Funds Weigh In On enGene

Several institutional investors have recently bought and sold shares of the stock. Fcpm Iii Services B.V. purchased a new position in enGene during the fourth quarter valued at $80,097,000. Goldman Sachs Group Inc. bought a new position in enGene during the fourth quarter valued at $346,000. Blue Owl Capital Holdings LP bought a new position in enGene during the fourth quarter valued at $11,397,000. Omega Fund Management LLC bought a new position in enGene during the fourth quarter valued at $10,441,000. Finally, BVF Inc. IL bought a new position in enGene during the fourth quarter valued at $20,777,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.